Kineta EPS - Earnings per Share 2014-2024 | KANT
Kineta eps - earnings per share from 2014 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Kineta Annual EPS |
| 2023 |
$-1.28 |
| 2022 |
$-12.87 |
| 2021 |
$-2.71 |
| 2020 |
$-150.95 |
| 2019 |
$-102.94 |
| 2018 |
$-225.33 |
| 2017 |
$-327.50 |
| 2016 |
$-288.31 |
| 2015 |
$-5,897.83 |
| 2014 |
$-8,920.92 |
| 2013 |
$-7,539.54 |
| Kineta Quarterly EPS |
| 2024-06-30 |
$-0.20 |
| 2024-03-31 |
$-0.89 |
| 2023-12-31 |
$-0.09 |
| 2023-09-30 |
$-0.46 |
| 2023-06-30 |
$0.04 |
| 2023-03-31 |
$-0.77 |
| 2022-12-31 |
$-9.43 |
| 2022-09-30 |
$-1.14 |
| 2022-06-30 |
$-1.23 |
| 2022-03-31 |
$-1.07 |
| 2021-12-31 |
$17.23 |
| 2021-09-30 |
$-6.79 |
| 2021-06-30 |
$-7.21 |
| 2021-03-31 |
$-5.95 |
| 2020-12-31 |
$-105.04 |
| 2020-09-30 |
$-20.71 |
| 2020-06-30 |
$-0.91 |
| 2020-03-31 |
$-24.28 |
| 2019-12-31 |
$25.82 |
| 2019-09-30 |
$-34.99 |
| 2019-06-30 |
$-54.58 |
| 2019-03-31 |
$-39.19 |
| 2018-12-31 |
$-50.39 |
| 2018-09-30 |
$-69.98 |
| 2018-06-30 |
$-60.18 |
| 2018-03-31 |
$-44.79 |
| 2017-12-31 |
$-69.98 |
| 2017-09-30 |
$-78.38 |
| 2017-06-30 |
$-95.17 |
| 2017-03-31 |
$-83.98 |
| 2016-12-31 |
$-25.19 |
| 2016-09-30 |
$-75.58 |
| 2016-06-30 |
$-65.78 |
| 2016-03-31 |
$-121.76 |
| 2015-12-31 |
$-1,431.77 |
| 2015-09-30 |
$-2,347.10 |
| 2015-06-30 |
$-64.38 |
| 2015-03-31 |
$-2,054.58 |
| 2014-12-31 |
$0.00 |
| 2013-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
